Literature DB >> 17036368

Synthesis and antibacterial activity of nitroaryl thiadiazole-levofloxacin hybrids.

Alireza Foroumadi1, Shahla Mansouri, Saeed Emami, Javad Mirzaei, Maedeh Sorkhi, Nosratollah Saeid-Adeli, Abbas Shafiee.   

Abstract

Novel levofloxacin-containing hybrids carrying a 5-(nitroaryl)-1,3,4-thiadiazol-2-yl group were synthesized and evaluated in vitro against Gram-positive and Gram-negative bacteria. Preliminary data indicated that levofloxacin-nitrofuran and levofloxacin-nitroimidazole hybrids have a potent activity against Gram-positive organisms with enhanced anti-staphylococcal activity compared with the parent quinolone (N-desmethyl levofloxacin).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036368     DOI: 10.1002/ardp.200600108

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  4 in total

1.  New 7-piperazinylquinolones containing (benzo[d]imidazol-2-yl)methyl moiety as potent antibacterial agents.

Authors:  Hojat-Allah Arab; Mohammad Ali Faramarzi; Nasrin Samadi; Hamid Irannejad; Alireza Foroumadi; Saeed Emami
Journal:  Mol Divers       Date:  2018-06-07       Impact factor: 2.943

2.  Synthesis of new 2-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-ylimino)thiazolidin-4-one derivatives as anti-MRSA and anti-H. pylori agents.

Authors:  Arash Tabei; Ramona Ejtemaei; Arash Mahboubi; Parastoo Saniee; Alireza Foroumadi; Alireza Dehdari; Ali Almasirad
Journal:  BMC Chem       Date:  2022-05-27

3.  Nature versus nurture in two highly enantioselective esterases from Bacillus cereus and Thermoanaerobacter tengcongensis.

Authors:  Stephan Grosse; Hélène Bergeron; Akihiro Imura; Jason Boyd; Shaozhao Wang; Kazuo Kubota; Akihiko Miyadera; Traian Sulea; Peter C K Lau
Journal:  Microb Biotechnol       Date:  2009-07-31       Impact factor: 5.813

4.  Synthesis and in vitro antimicrobial activity screening of new pipemidic acid derivatives.

Authors:  Łukasz Popiołek; Anna Biernasiuk; Kinga Paruch; Anna Malm; Monika Wujec
Journal:  Arch Pharm Res       Date:  2018-04-04       Impact factor: 4.946

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.